Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle Invasive Bladder Cancer × danvatirsen × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lymphoma, Large B-Cell, Diffuse 2 Turcot syndrome 1 Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Ascites 1 Advanced Solid Tumours 1 Advanced Solid Malignancies 1

Interventions

tislelizumab 2 vistusertib 1 toripalimab 1 olaparib 1 liposomal doxorubicin 1 durvalumab 1 disitamab vedotin 1 danvatirsen 1 adavosertib 1 Surgical Procedures, Operative 1 Rutin 1 Radiation 1 RC48 antibody 1 Gemcitabine 1 Cystectomy 1 Cisplatin 1 Chemoradiotherapy 1 AZD4547 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡